ESTROGEN/SERM AND ESTROGEN/PROGESTIN BI-LAYER TABLETS

• US 20080175905A1
• Filed: 11/28/2007
• Published: 07/24/2008
• Est. Priority Date: 11/29/2006
• Status: Abandoned Application

• Current Assignee: Wyeth LLC (Pfizer Inc.)
• Original Assignee: Wyeth (Pfizer Inc.)
• Inventors: Baksh, Nizamuddin, Enever, Robin, Kresevic, John, Liu, Xiuying
• Application Number:
  US11/946,586
• Publication Number:
  US 20080175905A1
• Time in Patent Office: Days
• US Class Current: 424/464
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/55 having seven-membered rings, e.g. azelastine, pentylenetetrazole
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/209 containing drug in at least two layers or in the core and in at least one outer layer
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/02 for disorders of the vagina
• CPC Class Codes: A61P 15/12 for climacteric disorders
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/24 of the sex hormones
• CPC Class Codes: A61P 5/30 Oestrogens
• CPC Class Codes: A61P 5/34 Gestagens
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention is directed to bi-layer tablets comprising at least one estrogen in a first layer and a therapeutic agent in a second layer, and processes for their preparation.

Claims

1. A bi-layer tablet comprising:

(a) a first layer comprising at least one estrogen; and

(b) a second layer comprising one or more therapeutic agents selected from the group consisting of a selective estrogen receptor modulator and a progestational agent.

2. The tablet of claim 1 wherein:

said first layer comprises from about 20% to about 45% by weight of said tablet; and

said second layer comprises from about 55% to about 80% by weight of said tablet.

3. The tablet of claim 1 wherein said estrogen comprises conjugated estrogens.

4. The tablet of claim 1 wherein said second layer comprises one or more therapeutic agents selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

5. The tablet of claim 4 wherein said therapeutic agent is 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, acetic acid salt.

6. The tablet of claim 1 wherein:

said estrogen comprises conjugated estrogens; and

said second layer comprises one or more therapeutic agents selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

7. The tablet of claim 1 wherein said first layer and said second layer each further independently comprise a hydrophilic gel-forming polymer component.

8. The tablet of claim 7 wherein:

said estrogen comprises conjugated estrogens; and

said second layer further comprises one or more therapeutic agents selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

9. The tablet of claim 8 wherein said hydrophilic gel-forming polymer component of said first layer and said hydrophilic gel-forming polymer component of said second layer each independently comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum.

10. The tablet of claim 8 wherein said hydrophilic gel-forming polymer component of said first layer and said hydrophilic gel-forming polymer component of said second layer each comprise hydroxypropylmethylcellulose.

11. The tablet of claim 7 wherein said hydrophilic gel-forming polymer component of said first layer and said hydrophilic gel-forming polymer component of said second layer each independently comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum.

12. The tablet of claim 7 wherein said hydrophilic gel-forming polymer component of said first layer and said hydrophilic gel-forming polymer component of said second layer each comprise hydroxypropylmethylcellulose.

13. The tablet of claim 7 wherein:

said hydrophilic gel-forming polymer component of said first layer comprises from about 5% to about 80% by weight of said first layer; and

said hydrophilic gel-forming polymer component of said second layer comprises from about 1% to about 40% by weight of said second layer.

14. The tablet of claim 13 wherein said hydrophilic gel-forming polymer component of said first layer and said hydrophilic gel-forming polymer component of said second layer each independently comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum.

15. The tablet of claim 13 wherein said hydrophilic gel-forming polymer component of said first layer and said hydrophilic gel-forming polymer component of said second layer each independently comprises hydroxpropylmethylcellulose.

16. The tablet of claim 13 wherein:

(a) said first layer further comprises;

a filler/diluent component comprising from about 10% to about 90% by weight of said first layer;

a filler/binder component comprising from about 0.1% to about 30% by weight of said first layer; and

optionally, a lubricant component comprising from about 0.01% to about 3% by weight of said first layer; and

(b) said second layer further comprises;

a filler/diluent component comprising from about 10% to about 75% by weight of said second layer;

a filler/binder component comprising up to about 60% by weight of said second layer;

optionally, a lubricant component comprising from about 0.01% to about 3% by weight of said second layer;

optionally, a disintegrant comprising up to about 4% by weight of said second layer; and

optionally, an antioxidant component comprising from about 0.01% to about 4% by weight of said second layer.

17. The tablet of claim 16 wherein:

said filler/diluent component of said first layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said first layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer component of said first layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said first layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said filler/diluent component of said second layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said second layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer of said second layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said second layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium, carmellose calcium, crospovidone, alginic acid, sodium alginate, potassium alginate, calcium alginate, starch, pregelatinized starch, sodium starch glycolate, cellulose floc, and carboxymethylcellulose; and

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid, sodium ascorbate, ascorbyl palmitate, vitamin E, vitamin E acetate, butylated hydroxytoluene, and butylated hydroxyanisole.

18. The tablet of claim 16 wherein

said filler/diluent component of said first layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said first layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said first layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said second layer, if present, comprises magnesium stearate;

said filler/diluent component of said second layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said second layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said second layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said second layer, if present, comprises magnesium stearate;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium; and

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid and vitamin E acetate.

19. The tablet of claim 7 wherein:

said hydrophilic gel-forming polymer component of said first layer comprises from about 30% to about 40% by weight of said first layer; and

said hydrophilic gel-forming polymer component of said second layer comprises from about 15% to about 30% by weight of said second layer.

20. The tablet of claim 19 wherein:

(a) said first layer further comprises;

a filler/diluent component comprising from about 30% to about 70% by weight of said first layer;

a filler/binder component comprising from about 5% to about 25% by weight of said first layer; and

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said first layer; and

(b) said second layer further comprises;

a filler/diluent component comprising from about 25% to about 50% by weight of said second layer;

a filler/binder component comprising from about 20% to about 60% by weight of said second layer;

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said second layer;

optionally, a disintegrant comprising up to about 4% by weight of said second layer; and

optionally, an antioxidant component comprising from about 0.01% to about 4% by weight of said second layer.

21. The tablet of claim 20 wherein:

said filler/diluent component of said first layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said first layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer component of said first layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said first layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said filler/diluent component of said second layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said second layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer of said second layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said second layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium, carmellose calcium, crospovidone, alginic acid, sodium alginate, potassium alginate, calcium alginate, starch, pregelatinized starch, sodium starch glycolate, cellulose floc, and carboxymethylcellulose;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid, sodium ascorbate, ascorbyl palmitate, vitamin E, vitamin E acetate, butylated hydroxytoluene, and butylated hydroxyanisole;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

22. The tablet of claim 20 wherein:

said filler/diluent component of said first layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said first layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said first layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said first layer, if present, comprises magnesium stearate;

said filler/diluent component of said second layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said second layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said second layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said second layer, if present, comprises magnesium stearate;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid and vitamin E acetate;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

23. The tablet of claim 7 wherein:

said hydrophilic gel-forming polymer component of said first layer comprises from about 5% to about 15% by weight of said first layer; and

said hydrophilic gel-forming polymer component of said second layer comprises from about 15% to about 30% by weight of said second layer.

24. The tablet of claim 23 wherein:

(a) said first layer further comprises;

a filler/diluent component comprising from about 50% to about 85% by weight of said first layer;

a filler/binder component comprising from about 5% to about 25% by weight of said first layer; and

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said first layer; and

(b) said second layer further comprises;

a filler/diluent component comprising from about 20% to about 60% by weight of said second layer;

a filler/binder component comprising from about 20% to about 60% by weight of said second layer;

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said second layer;

optionally, a disintegrant comprising up to about 4% by weight of said second layer; and

optionally, an antioxidant component comprising from about 0.01% to about 4% by weight of said second layer.

25. The tablet of claim 24 wherein:

said filler/diluent component of said first layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said first layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer component of said first layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said first layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said filler/diluent component of said second layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said second layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer of said second layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said second layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium, carmellose calcium, crospovidone, alginic acid, sodium alginate, potassium alginate, calcium alginate, starch, pregelatinized starch, sodium starch glycolate, cellulose floc, and carboxymethylcellulose;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid, sodium ascorbate, ascorbyl palmitate, vitamin E, vitamin E acetate, butylated hydroxytoluene, and butylated hydroxyanisole;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

26. The tablet of claim 24 wherein:

said filler/diluent component of said first layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said first layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said first layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said first layer, if present, comprises magnesium stearate;

said filler/diluent component of said second layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said second layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said second layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said second layer, if present, comprises magnesium stearate;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid and vitamin E acetate;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

27. The tablet of claim 7 wherein:

said hydrophilic gel-forming polymer component of said first layer comprises from about 30% to about 40% by weight of said first layer; and

said hydrophilic gel-forming polymer component of said second layer comprises from about 1% to about 8% by weight of said second layer.

28. The tablet of claim 27 wherein:

(a) said first layer further comprises;

a filler/diluent component comprising from about 30% to about 70% by weight of said first layer;

a filler/binder component comprising from about 5% to about 25% by weight of said first layer; and

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said first layer; and

(b) said second layer further comprises;

a filler/diluent component comprising from about 35% to about 75% by weight of said second layer;

a filler/binder component comprising from about 20% to about 60% by weight of said second layer;

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said second layer;

optionally, a disintegrant comprising up to about 4% by weight of said second layer; and

optionally, an antioxidant component comprising from about 0.01% to about 4% by weight of said second layer.

29. The tablet of claim 28 wherein:

said filler/diluent component of said first layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said first layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer component of said first layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said first layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said filler/diluent component of said second layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said second layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer of said second layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said second layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium, carmellose calcium, crospovidone, alginic acid, sodium alginate, potassium alginate, calcium alginate, starch, pregelatinized starch, sodium starch glycolate, cellulose floc, and carboxymethylcellulose;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid, sodium ascorbate, ascorbyl palmitate, vitamin E, vitamin E acetate, butylated hydroxytoluene, and butylated hydroxyanisole;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

30. The tablet of claim 28 wherein:

said filler/diluent component of said first layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said first layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said first layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said first layer, if present, comprises magnesium stearate;

said filler/diluent component of said second layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said second layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said second layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said second layer, if present, comprises magnesium stearate;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid and vitamin E acetate;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

31. The tablet of claim 7 wherein:

said hydrophilic gel-forming polymer component of said first layer comprises from about 5% to about 15% by weight of said first layer; and

said hydrophilic gel-forming polymer component of said second layer comprises from about 1% to about 8% by weight of said second layer.

32. The tablet of claim 31 wherein:

(a) said first layer further comprises;

a filler/diluent component comprising from about 50% to about 85% by weight of said first layer;

a filler/binder component comprising from about 5% to about 25% by weight of said first layer; and

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said first layer; and

(b) said second layer further comprises;

a filler/diluent component comprising from about 35% to about 75% by weight of said second layer;

a filler/binder component comprising from about 20% to about 60% by weight of said second layer;

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said second layer;

optionally, a disintegrant comprising up to about 4% by weight of said second layer; and

optionally, an antioxidant component comprising from about 0.01% to about 4% by weight of said second layer.

33. The tablet of claim 32 wherein:

said filler/diluent component of said first layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said first layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer component of said first layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said first layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said filler/diluent component of said second layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said second layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer of said second layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said second layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium, carmellose calcium, crospovidone, alginic acid, sodium alginate, potassium alginate, calcium alginate, starch, pregelatinized starch, sodium starch glycolate, cellulose floc, and carboxymethylcellulose;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid, sodium ascorbate, ascorbyl palmitate, vitamin E, vitamin E acetate, butylated hydroxytoluene, and butylated hydroxyanisole;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

34. The tablet of claim 32 wherein:

said filler/diluent component of said first layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said first layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said first layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said first layer, if present, comprises magnesium stearate;

said filler/diluent component of said second layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said second layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said second layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said second layer, if present, comprises magnesium stearate;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid and vitamin E acetate;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

35. The tablet of claim 7 wherein:

said hydrophilic gel-forming polymer component of said first layer comprises from about 30% to about 40% by weight of said first layer; and

said hydrophilic gel-forming polymer component of said second layer comprises from about 8% to about 15% by weight of said second layer.

36. The tablet of claim 35 wherein:

(a) said first layer further comprises;

a filler/diluent component comprising from about 30% to about 70% by weight of said first layer;

a filler/binder component comprising from about 5% to about 25% by weight of said first layer; and

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said first layer; and

(b) said second layer further comprises;

a filler/diluent component comprising from about 35% to about 70% by weight of said second layer;

a filler/binder component comprising from about 20% to about 60% by weight of said second layer;

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said second layer;

optionally, a disintegrant comprising up to about 4% by weight of said second layer; and

optionally, an antioxidant component comprising from about 0.01% to about 4% by weight of said second layer.

37. The tablet of claim 36 wherein:

said filler/diluent component of said first layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said first layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer component of said first layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said first layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said filler/diluent component of said second layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said second layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer of said second layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said second layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium, carmellose calcium, crospovidone, alginic acid, sodium alginate, potassium alginate, calcium alginate, starch, pregelatinized starch, sodium starch glycolate, cellulose floc, and carboxymethylcellulose;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid, sodium ascorbate, ascorbyl palmitate, vitamin E, vitamin E acetate, butylated hydroxytoluene, and butylated hydroxyanisole;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

38. The tablet of claim 36 wherein:

said filler/diluent component of said first layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said first layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said first layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said first layer, if present, comprises magnesium stearate;

said filler/diluent component of said second layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said second layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said second layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said second layer, if present, comprises magnesium stearate;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid and vitamin E acetate;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

39. The tablet of claim 7 wherein:

said hydrophilic gel-forming polymer component of said first layer comprises from about 40% to about 60% by weight of said first layer; and

said hydrophilic gel-forming polymer component of said second layer comprises from about 1% to about 8% by weight of said second layer.

40. The tablet of claim 39 wherein:

(a) said first layer further comprises;

a filler/diluent component comprising from about 10% to about 50% by weight of said first layer;

a filler/binder component comprising from about 5% to about 25% by weight of said first layer; and

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said first layer; and

(b) said second layer further comprises;

a filler/diluent component comprising from about 35% to about 75% by weight of said second layer;

a filler/binder component comprising from about 20% to about 60% by weight of said second layer;

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said second layer;

optionally, a disintegrant comprising up to about 4% by weight of said second layer; and

optionally, an antioxidant component comprising from about 0.01% to about 4% by weight of said second layer.

41. The tablet of claim 40 wherein:

said filler/diluent component of said first layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said first layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer component of said first layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said first layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said filler/diluent component of said second layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said second layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer of said second layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said second layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium, carmellose calcium, crospovidone, alginic acid, sodium alginate, potassium alginate, calcium alginate, starch, pregelatinized starch, sodium starch glycolate, cellulose floc, and carboxymethylcellulose;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid, sodium ascorbate, ascorbyl palmitate, vitamin E, vitamin E acetate, butylated hydroxytoluene, and butylated hydroxyanisole;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

42. The tablet of claim 40 wherein:

said filler/diluent component of said first layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said first layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said first layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said first layer, if present, comprises magnesium stearate;

said filler/diluent component of said second layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said second layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said second layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said second layer, if present, comprises magnesium stearate;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid and vitamin E acetate;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

43. The tablet of claim 7 wherein:

said hydrophilic gel-forming polymer component of said first layer comprises from about 40% to about 60% by weight of said first layer; and

said hydrophilic gel-forming polymer component of said second layer comprises from about 8% to about 15% by weight of said second layer.

44. The tablet of claim 43 wherein:

(a) said first layer further comprises;

a filler/diluent component comprising from about 10% to about 50% by weight of said first layer;

a filler/binder component comprising from about 5% to about 25% by weight of said first layer; and

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said first layer; and

(b) said second layer further comprises;

a filler/diluent component comprising from about 35% to about 70% by weight of said second layer;

a filler/binder component comprising from about 20% to about 60% by weight of said second layer;

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said second layer;

optionally, a disintegrant comprising up to about 4% by weight of said second layer; and

optionally, an antioxidant component comprising from about 0.01% to about 4% by weight of said second layer.

45. The tablet of claim 44 wherein:

said filler/diluent component of said first layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said first layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer component of said first layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said first layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said filler/diluent component of said second layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said second layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer of said second layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said second layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium, carmellose calcium, crospovidone, alginic acid, sodium alginate, potassium alginate, calcium alginate, starch, pregelatinized starch, sodium starch glycolate, cellulose floc, and carboxymethylcellulose;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid, sodium ascorbate, ascorbyl palmitate, vitamin E, vitamin E acetate, butylated hydroxytoluene, and butylated hydroxyanisole;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

46. The tablet of claim 44 wherein:

said filler/diluent component of said first layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said first layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said first layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said first layer, if present, comprises magnesium stearate;

said filler/diluent component of said second layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said second layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said second layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said second layer, if present, comprises magnesium stearate;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid and vitamin E acetate;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

47. The tablet of claim 7 wherein:

said hydrophilic gel-forming polymer component of said first layer comprises from about 40% to about 60% by weight of said first layer; and

said hydrophilic gel-forming polymer component of said second layer comprises from about 15% to about 30% by weight of said second layer.

48. The tablet of claim 47 wherein:

(a) said first layer further comprises;

a filler/diluent component comprising from about 10% to about 50% by weight of said first layer;

a filler/binder component comprising from about 5% to about 25% by weight of said first layer; and

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said first layer; and

(b) said second layer further comprises;

a filler/diluent component comprising from about 20% to about 60% by weight of said second layer;

a filler/binder component comprising from about 20% to about 60% by weight of said second layer;

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said second layer;

optionally, a disintegrant comprising up to about 4% by weight of said second layer; and

optionally, an antioxidant component comprising from about 0.01% to about 4% by weight of said second layer.

49. The tablet of claim 48 wherein:

said filler/diluent component of said first layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said first layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer component of said first layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said first layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said filler/diluent component of said second layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said second layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer of said second layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said second layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium, carmellose calcium, crospovidone, alginic acid, sodium alginate, potassium alginate, calcium alginate, starch, pregelatinized starch, sodium starch glycolate, cellulose floc, and carboxymethylcellulose;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid, sodium ascorbate, ascorbyl palmitate, vitamin E, vitamin E acetate, butylated hydroxytoluene, and butylated hydroxyanisole;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

50. The tablet of claim 48 wherein:

said filler/diluent component of said first layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said first layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said first layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said first layer, if present, comprises magnesium stearate;

said filler/diluent component of said second layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said second layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said second layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said second layer, if present, comprises magnesium stearate;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid and vitamin E acetate;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

51. The tablet of claim 7 wherein:

said hydrophilic gel-forming polymer component of said first layer comprises from about 5% to about 15% by weight of said first layer; and

said hydrophilic gel-forming polymer component of said second layer comprises from about 8% to about 15% by weight of said second layer.

52. The tablet of claim 51 wherein:

(a) said first layer further comprises;

a filler/diluent component comprising from about 50% to about 85% by weight of said first layer;

a filler/binder component comprising from about 5% to about 25% by weight of said first layer; and

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said first layer; and

(b) said second layer further comprises;

a filler/diluent component comprising from about 35% to about 70% by weight of said second layer;

a filler/binder component comprising from about 20% to about 60% by weight of said second layer;

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said second layer;

optionally, a disintegrant comprising up to about 4% by weight of said second layer; and

optionally, an antioxidant component comprising from about 0.01% to about 4% by weight of said second layer.

53. The tablet of claim 52 wherein:

said filler/diluent component of said first layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said first layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer component of said first layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said first layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said filler/diluent component of said second layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said second layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer of said second layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said second layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium, carmellose calcium, crospovidone, alginic acid, sodium alginate, potassium alginate, calcium alginate, starch, pregelatinized starch, sodium starch glycolate, cellulose floc, and carboxymethylcellulose;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid, sodium ascorbate, ascorbyl palmitate, vitamin E, vitamin E acetate, butylated hydroxytoluene, and butylated hydroxyanisole;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

54. The tablet of claim 52 wherein:

said filler/diluent component of said first layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said first layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said first layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said first layer, if present, comprises magnesium stearate;

said filler/diluent component of said second layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said second layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said second layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said second layer, if present, comprises magnesium stearate;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid and vitamin E acetate;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

55. The tablet of claim 7 wherein:

said hydrophilic gel-forming polymer component of said first layer comprises from about 15% to about 30% by weight of said first layer; and

said hydrophilic gel-forming polymer component of said second layer comprises from about 15% to about 30% by weight of said second layer.

56. The tablet of claim 55 wherein:

(a) said first layer further comprises;

a filler/diluent component comprising from about 40% to about 80% by weight of said first layer;

a filler/binder component comprising from about 5% to about 25% by weight of said first layer; and

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said first layer; and

(b) said second layer further comprises;

a filler/diluent component comprising from about 0.0% to about 60% by weight of said second layer;

a filler/binder component comprising from about 20% to about 60% by weight of said second layer; and

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said second layer;

optionally, a disintegrant comprising up to about 4% by weight of said second layer; and

optionally, an antioxidant component comprising from about 0.01% to about 4% by weight of said second layer.

57. The tablet of claim 56 wherein:

said filler/diluent component of said first layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said first layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer component of said first layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said first layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said filler/diluent component of said second layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said second layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer of said second layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said second layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium, carmellose calcium, crospovidone, alginic acid, sodium alginate, potassium alginate, calcium alginate, starch, pregelatinized starch, sodium starch glycolate, cellulose floc, and carboxymethylcellulose;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid, sodium ascorbate, ascorbyl palmitate, vitamin E, vitamin E acetate, butylated hydroxytoluene, and butylated hydroxyanisole;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

58. The tablet of claim 56 wherein:

said filler/diluent component of said first layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said first layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said first layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said first layer, if present, comprises magnesium stearate;

said filler/diluent component of said second layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said second layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said second layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said second layer, if present, comprises magnesium stearate;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid and vitamin E acetate;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

59. The tablet of claim 7 wherein:

said hydrophilic gel-forming polymer component of said first layer comprises from about 15% to about 30% by weight of said first layer; and

said hydrophilic gel-forming polymer component of said second layer comprises from about 1% to about 8% by weight of said second layer.

60. The tablet of claim 59 wherein:

(a) said first layer further comprises;

a filler/diluent component comprising from about 40% to about 80% by weight of said first layer;

a filler/binder component comprising from about 5% to about 25% by weight of said first layer; and

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said first layer; and

(b) said second layer further comprises;

a filler/diluent component comprising from about 35% to about 75% by weight of said second layer;

a filler/binder component comprising from about 20% to about 60% by weight of said second layer;

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said second layer;

optionally, a disintegrant comprising up to about 4% by weight of said second layer; and

optionally, an antioxidant component comprising from about 0.01% to about 4% by weight of said second layer.

61. The tablet of claim 60 wherein:

said filler/diluent component of said first layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said first layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer component of said first layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said first layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said filler/diluent component of said second layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said second layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer of said second layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said second layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium, carmellose calcium, crospovidone, alginic acid, sodium alginate, potassium alginate, calcium alginate, starch, pregelatinized starch, sodium starch glycolate, cellulose floc, and carboxymethylcellulose;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid, sodium ascorbate, ascorbyl palmitate, vitamin E, vitamin E acetate, butylated hydroxytoluene, and butylated hydroxyanisole;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

62. The tablet of claim 60 wherein:

said filler/diluent component of said first layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said first layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said first layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said first layer, if present, comprises magnesium stearate;

said filler/diluent component of said second layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said second layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said second layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said second layer, if present, comprises magnesium stearate;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid and vitamin E acetate;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

63. The tablet of claim 7 wherein:

said hydrophilic gel-forming polymer component of said first layer comprises from about 15% to about 30% by weight of said first layer; and

said hydrophilic gel-forming polymer component of said second layer comprises from about 8% to about 15% by weight of said second layer.

64. The tablet of claim 63 wherein

(a) said first layer further comprises:

a filler/diluent component comprising from about 40% to about 80% by weight of said first layer;

a filler/binder component comprising from about 5% to about 25% by weight of said first layer; and

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said first layer; and

(b) said second layer further comprises;

a filler/diluent component comprising from about 35% to about 70% by weight of said second layer;

a filler/binder component comprising from about 20% to about 60% by weight of said second layer;

optionally, a lubricant component comprising from about 0.01% to about 2% by weight of said second layer;

optionally, a disintegrant comprising up to about 4% by weight of said second layer; and

optionally, an antioxidant component comprising from about 0.01% to about 4% by weight of said second layer.

65. The tablet of claim 64 wherein:

said filler/diluent component of said first layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said first layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer component of said first layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said first layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said filler/diluent component of said second layer comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said second layer comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer of said second layer comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said second layer, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium, carmellose calcium, crospovidone, alginic acid, sodium alginate, potassium alginate, calcium alginate, starch, pregelatinized starch, sodium starch glycolate, cellulose floc, and carboxymethylcellulose;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid, sodium ascorbate, ascorbyl palmitate, vitamin E, vitamin E acetate, butylated hydroxytoluene, and butylated hydroxyanisole;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

66. The tablet of claim 64 wherein:

said filler/diluent component of said first layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said first layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said first layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said first layer, if present, comprises magnesium stearate;

said filler/diluent component of said second layer comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said second layer comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said second layer comprises hydroxypropylmethylcellulose;

said optional lubricant component of said second layer, if present, comprises magnesium stearate;

said optional disintegrant of said second layer, if present, comprises croscarmellose sodium;

said optional antioxidant component of said second layer, if present, comprises one or more of ascorbic acid and vitamin E acetate;

said estrogen comprises conjugated estrogens; and

said one or more therapeutic agents are selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

67. A tablet selected from a plurality of tablets according to claim 7, wherein the plurality has a mean dissolution profile wherein:

the mean of % of the estrogen released per tablet after 1, 2, 3, 4, and 5 hours under estrogen dissolution conditions is substantially equal to the sum of f, a*A, b*B, c*A², d*B², and e*A*B; and

the mean of % of the therapeutic agent per tablet released after 0.25, 0.5, 1, 2, and 6 hours under type I therapeutic agent dissolution conditions is substantially equal to the sum of m, n*A, o*B, p*A², q*B², and r*A*B;

wherein;

A is the % of hydrophilic gel-forming polymer by weight of said first layer;

B is the % of hydrophilic gel-forming polymer by weight of said second layer;

f, at 1 hour, is 84.405;

a, at 1 hour, is −

1.801;

b, at 1 hour, is −

3.141;

c, at 1 hour, is 0.0159;

d, at 1 hour, is 0.0991;

e, at 1 hour, is 0.00609;

f, at 2 hours, is 112.029;

a, at 2 hours, is −

1.825;

b, at 2 hours, is −

4.401;

c, at 2 hours, is 0.0134;

d, at 2 hours, is 0.131;

e, at 2 hours, is 0.00794;

f, at 3 hours, is 128.469;

a, at 3 hours, is −

1.687;

b, at 3 hours, is −

5.218;

c, at 3 hours, is 0.0105;

d, at 3 hours, is 0.153;

e, at 3 hours, is 0.00741;

f, at 4 hours, is 133.525;

a, at 4 hours, is −

1.437;

b, at 4 hours, is −

5.053;

c, at 4 hours, is 0.00776;

d, at 4 hours, is 0.152;

e, at 4 hours, is 0.000658;

f, at 5 hours, is 133.182;

a, at 5 hours, is −

1.064;

b, at 5 hours, is −

4.893;

c, at 5 hours, is 0.004363;

d, at 5 hours, is 0.1558;

e, at 5 hours, is −

0.0076;

m, at 0.25 hour, is 94.7399;

n, at 0.25 hour, is −

0.2561;

o, at 0.25 hour, is −

10.7494;

p, at 0.25 hour, is −

0.0038874;

q, at 0.25 hour, is 0.3088;

r, at 0.25 hour, is 0.02228;

m, at 0.5 hour, is 113.1339;

n, at 0.5 hour, is −

0.2832;

o, at 0.5 hour, is −

12.549;

p, at 0.5 hour, is −

0.00428;

q, at 0.5 hour, is 0.35267;

r, at 0.5 hour, is 0.025698;

m, at 1 hour, is 133.966;

n, at 1 hour, is −

0.446;

o, at 1 hour, is −

14.0527;

p, at 1 hour, is −

0.0021667;

q, at 1 hour, is 0.38816;

r, at 1 hour, is 0.02607;

m, at 2 hours, is 153.718;

n, at 2 hours, is −

0.8427;

o, at 2 hours, is −

14.196;

p, at 2 hours, is 0.003872;

q, at 2 hours, is 0.38144;

r, at 2 hours, is 0.023435;

m, at 6 hours, is 133.7326;

n, at 6 hours, is −

1.134;

o, at 6 hours, is −

4.458;

p, at 6 hours, is 0.0115;

q, at 6 hours, is 0.05789; and

r, at 6 hours, is 0.0006761.

68. The tablet according to claim 67 wherein:

said hydrophilic gel-forming polymer component of said first layer comprises from about 5% to about 80% by weight of said first layer; and

said hydrophilic gel-forming polymer component of said second layer comprises from about 1% to about 40% by weight of said second layer.

69. The tablet of claim 1 wherein:

said estrogen comprises conjugated estrogens;

said therapeutic agent comprises medroxyprogesterone acetate;

said dissolution profile of said estrogen from said tablet under estrogen dissolution conditions is substantially as shown in any one of FIGS. 9 to 16 and 32 to 46; and

said dissolution profile of said therapeutic agent from said tablet under type I therapeutic agent dissolution conditions is substantially as shown in any one of FIGS. 1 to 8 and 17 to 31.

70. The tablet of claim 1 wherein:

said estrogen comprises conjugated estrogens;

said therapeutic agent comprises 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, acetic acid salt;

said dissolution profile of said estrogen from said tablet under estrogen dissolution conditions is substantially as shown in any one of FIGS. 50 to 52; and

said dissolution profile of said therapeutic agent from said tablet under type II therapeutic agent dissolution conditions is substantially as shown in any one of FIGS. 47 to 49.

71. A process for producing a bi-layer tablet of claim 1 comprising compressing together:

a first mixture comprising at least one estrogen; and

a second mixture comprising one or more therapeutic agents selected from the group consisting of a selective estrogen receptor modulator and a progestational agent.

72. The process of claim 71 wherein:

said estrogen comprises conjugated estrogens; and

said second mixture comprises one or more therapeutic agents selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

73. The process of claim 71 wherein said first mixture is prepared by a process comprising the steps of:

(i) mixing said estrogen and a hydrophilic gel-forming polymer component to form an initial mixture;

(ii) granulating said initial mixture to form a first granulated mixture; and

(iii) milling said first granulated mixture.

74. The process of claim 73 wherein step (i) further comprises mixing said estrogen and said hydrophilic gel-forming polymer component with a filler/diluent component and a filler/binder component.

75. The process of claim 74 wherein step (ii) further comprises the steps of:

(x) adding water to said initial mixture during said granulating; and

(y) drying said first granulated mixture before said milling.

76. The process of claim 75 wherein said drying comprises drying said first granulated mixture to loss on drying (LOD) of from about 1% to about 3%.

77. The process of claim 74 wherein said second mixture is prepared by a process comprising blending said therapeutic agent and a hydrophilic gel-forming polymer component.

78. The process of claim 77 wherein said blending of said therapeutic agent and said hydrophilic gel-forming polymer further comprises blending with a filler/diluent component, a filler/binder component, optionally, an antioxidant component and, optionally, a disintegrant.

79. The process of claim 78 further comprising granulating said second mixture after said blending of said therapeutic agent, said hydrophilic gel-forming polymer filler/diluent component, said filler/binder component, said optional antioxidant component and said optional disintegrant.

80. The process of claim 79 further comprising:

blending said first mixture with a lubricant after said milling; and

blending said second mixture with a lubricant after said blending of said therapeutic agent, said filler/diluent component, said filler/binder component, said hydrophilic gel-forming polymer component, said optional antioxidant component, if present, and said optional disintegrant component, if present.

81. A product of the process of claim 80.

82. The process of claim 71 wherein:

(a) said first mixture further comprises;

a filler/diluent component comprising from about 10% to about 90% by weight of said first mixture;

a filler/binder component comprising from about 0.1% to about 30% by weight of said first mixture;

a hydrophilic gel-forming polymer component comprising from about 5% to about 80% by weight of said first mixture; and

optionally, a lubricant component comprising from about 0.01% to about 3% by weight of said first mixture; and

(b) said second mixture further comprises;

a filler/diluent component comprising from about 10% to about 75% by weight of said second mixture;

a filler/binder component comprising up to about 60% by weight of said second mixture;

a hydrophilic gel-forming polymer component comprising from about 1% to about 40% by weight of said second mixture;

optionally, a lubricant component comprising from about 0.01% to about 3% by weight of said second mixture;

optionally, a disintegrant comprising up to about 4% by weight of said second mixture; and

optionally, an antioxidant component comprising from about 0.01% to about 4% by weight of said second mixture.

83. The process of claim 82 wherein:

said filler/diluent component of said first mixture comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said first mixture comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer component of said first mixture comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said first mixture, if present comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said filler/diluent component of said second mixture comprises one or more of lactose, lactose monohydrate, mannitol, sucrose, maltodextrin, dextrin, maltitol, sorbitol, xylitol, powdered cellulose, cellulose gum, microcrystalline cellulose, starch, calcium phosphate, and a metal carbonate;

said filler/binder component of said second mixture comprises one or more of microcrystalline cellulose, polyvinylpyrrolidone, copovidone, polyvinylalcohol, starch, gelatin, gum arabic, gum acacia, and gum tragacanth;

said hydrophilic gel-forming polymer of said second mixture comprises one or more of hydroxypropylmethylcellulose, polyethylene oxide, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, xanthan gum, and guar gum;

said optional lubricant component of said second mixture, if present, comprises one or more of stearic acid, metallic stearate, sodium stearyl fumarate, fatty acid, fatty alcohol, fatty acid ester, glyceryl behenate, mineral oil, vegetable oil, paraffin, leucine, talc, propylene glycol fatty acid ester, polyethylene glycol, polypropylene glycol, and polyalkylene glycol;

said optional disintegrant of said second mixture, if present, comprises croscarmellose sodium, carmellose calcium, crospovidone, alginic acid, sodium alginate, potassium alginate, calcium alginate, starch, pregelatinized starch, sodium starch glycolate, cellulose floc, and carboxymethylcellulose; and

said optional antioxidant component of said second mixture, if present, comprises one or more of ascorbic acid, sodium ascorbate, ascorbyl palmitate, vitamin E, vitamin E acetate, butylated hydroxytoluene, and butylated hydroxyanisole.

84. The process of claim 82 wherein

said filler/diluent component of said first mixture comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said first mixture comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said first mixture comprises hydroxypropylmethylcellulose;

said optional lubricant component of said first mixture, if present, comprises magnesium stearate;

said filler/diluent component of said second mixture comprises one or more of lactose or lactose monohydrate;

said filler/binder component of said second mixture comprises microcrystalline cellulose;

said hydrophilic gel-forming polymer component of said second mixture comprises hydroxypropylmethylcellulose;

said optional lubricant component of said second mixture, if present, comprises magnesium stearate;

said optional disintegrant of said second mixture, if present, comprises croscarmellose sodium; and

said optional antioxidant component of said second mixture, if present, comprises one or more of ascorbic acid and vitamin E acetate.

85. The process of claim 84 wherein:

said first mixture comprises conjugated estrogens; and

said second mixture comprises one or more therapeutic agents selected from the group consisting of medroxyprogesterone acetate and 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, or pharmaceutically acceptable salt thereof.

86. A product of the process of claim 85.